2024-03-20 13:30:20 ET
BioNTech SE (BNTX)
Q4 2023 Earnings Conference Call
March 20, 2024, 08:00 AM ET
Company Participants
Victoria Meissner - VP, Strategy and IR
Ugur Sahin - Co-Founder and CEO
Ozlem Tureci - Chief Medical Officer and Co-Founder
Jens Holstein - CFO
Ryan Richardson - Chief Strategy Officer
Conference Call Participants
Daina Graybosch - Leerink Partners
Bill Maughan - Canaccord
Ivy Wang - Jefferies
Yaron Werber - TD Cowen
Etzer Darout - BMO Capital
Jessica Fye - JPMorgan
Simon Baker - Redburn
Sara Vernizzi - UBS
Emmanuel Papadakis - Deutsche Bank
Presentation
Operator
Welcome to the BioNTech's Fourth Quarter and Full Year 2023 Earnings Call.
I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead.
Victoria Meissner
Thank you, good morning and good afternoon. Thank you for joining BioNTech's fourth quarter and full Year 2023 earnings call. As a reminder, the slides, we'll be using during this call and the corresponding press release we issued this morning, can be found in the Investor Relations section of our website.
On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings, with the U.S. Securities and Exchange Commission. Forward-looking statements in this call are subject to significant risks and uncertainties, speak only as of the date of this conference call and we undertake no obligation to update or revise any of these statements.
On Slide 3, you can find the agenda for today's call. Today, I'm joined by the following members of BioNTech's management team, Ugur Sahin, our CEO and Co-Founder; Ozlem Tureci, Chief Medical Officer and Co-Founder; Jens Holstein, Chief Financial Officer; and Ryan Richardson, Chief Strategy Officer.
With this, I would like to hand over to Ugur.
Ugur Sahin
Thank you, Victoria. A warm welcome to all those joining us today.
Slide 5. Let me start by reiterating our vision and company goals. BioNTech was founded 15 years ago with the vision to harness the power of the immune system, to fight human diseases, particularly cancer. The emergence of the pandemic accelerated our mission, leading to the development of our COVID-19 vaccine. This achievement not only showcased the versatility of our mRNA technology, but also highlighted our unique expertise and ability to execute fast.
Our vision was realized and broadened, illuminating the potential of our science across other therapeutic areas. Building on this, our three objectives moving forward are. To establish a multiproduct company powered by our pioneering technologies and science, to address medical needs worldwide.
To contribute to the development of innovative precision medicines against cancer, aiming for multiple product approvals in the coming years. And to expand and strengthen our sustainable respiratory infectious disease vaccine business, building on the success of our COMIRNATY franchise....
Read the full article on Seeking Alpha
For further details see:
BioNTech SE (BNTX) Q4 2023 Earnings Call Transcript